Karl Keegan appointed new e-therapeutics finance chief

Network biology technology company e-therapeutics announced the appointment of Dr Karl Keegan as its chief financial officer in a non-board capacity with immediate effect on Monday.

The AIM-traded firm said Dr Keegan had more than 20 years of experience in the pharmaceutical and biotech industries.

It said that after working in academia and large pharma, he became a sell-side analyst at a number of investment banks.

Since 2009, he held senior executive roles in private and public companies, most recently as chief executive officer of the privately-held Hox Therapeutics Limited.

“I am delighted to be joining the e-therapeutics team at such a pivotal time for the company,” said Dr Karl Keegan.

“The company has built an impressive computational biology drug discovery platform and clinically validated RNA interference drug modality.”

The board said Dr Keegan received his BSc in pharmacology from University College Dublin, MPhil and PhD degrees from the University of Cambridge, and his MSc in finance from the London Business School.

“We are delighted to welcome Karl to e-therapeutics at this point in the company's evolution,” said CEO Ali Mortazavi.

“The combination of his industry and financial sector expertise will be a major addition to the team.”

At 1604 BST, shares in e-therapeutics were down 4.23% at 21.5p.